Vantage logo

Darzalex's ambitions extend beyond Maia

Data from quad therapy and a subcutaneous formulation could resuscitate enthusiasm even if the US government shutdown delays Darzalex's upcoming first-line approval.

Vantage logo

Solid guns for Sarepta

Solid Biosciences should soon find out if its DMD gene therapy, SGT-001, could compete with Sarepta’s.

Vantage logo

FDA panel to act on Impulse

An adcom for Impulse Dynamics’ heart muscle stimulator is approaching, and the group will want to avoid a nasty shock.